OA11592A - Substituted imidazo!1,2aÜazines as selective inhibitors of cox-2. - Google Patents

Substituted imidazo!1,2aÜazines as selective inhibitors of cox-2. Download PDF

Info

Publication number: OA11592A
Authority: OA; OAPI
Prior art keywords: imidazo; methylsulfonylphenyl; pyridine; pyrimidine; aminosulfonylphenyl
Prior art date: 1998-08-03

Application number

OA1200100033A

Other languages

English (en)

Inventor

Gallemi Carles Farrerons

Ignacio-Jose Miquel Bono

Ana Maria Fernandez Serrat

Carlos Monserrat Vidal

Carmen Lagunas Arnal

Ferran Gimenez Guasch

Andres Fernandez Garcia

Original Assignee

Salvat Lab Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-03

Filing date

1999-07-23

Publication date

2004-07-30

1999-07-23 Application filed by Salvat Lab Sa filed Critical Salvat Lab Sa

2004-07-30 Publication of OA11592A publication Critical patent/OA11592A/en

Links

101150071146 COX2 gene Proteins 0.000 title 1
101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 title 1
101150000187 PTGS2 gene Proteins 0.000 title 1
229940124639 Selective inhibitor Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 91
229910052794 bromium Inorganic materials 0.000 claims abstract description 15
229910052801 chlorine Inorganic materials 0.000 claims abstract description 15
229910052731 fluorine Inorganic materials 0.000 claims abstract description 13
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
201000010099 disease Diseases 0.000 claims abstract description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 10
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 7
230000001404 mediated effect Effects 0.000 claims abstract description 6
239000002798 polar solvent Substances 0.000 claims abstract description 5
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 5
238000000034 method Methods 0.000 claims description 37
-1 4-methylsulfonylphenyl Chemical group 0.000 claims description 35
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 35
UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims description 33
INSWZAQOISIYDT-UHFFFAOYSA-N imidazo[1,2-a]pyrimidine Chemical compound C1=CC=NC2=NC=CN21 INSWZAQOISIYDT-UHFFFAOYSA-N 0.000 claims description 31
FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims description 25
239000008194 pharmaceutical composition Substances 0.000 claims description 7
230000004054 inflammatory process Effects 0.000 claims description 6
230000005764 inhibitory process Effects 0.000 claims description 6
206010061218 Inflammation Diseases 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
MGGFNZWFWJBUPD-UHFFFAOYSA-N 2-(4-ethoxyphenyl)-3-(4-methylsulfonylphenyl)imidazo[1,2-a]pyrimidine Chemical compound C1=CC(OCC)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)N2C=CC=NC2=N1 MGGFNZWFWJBUPD-UHFFFAOYSA-N 0.000 claims description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
YSWWOBKIEHJRSO-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridine Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)N2C=CC=CC2=N1 YSWWOBKIEHJRSO-UHFFFAOYSA-N 0.000 claims description 3
SSARXDLPJGIOOC-UHFFFAOYSA-N 2-(4-methoxyphenyl)-3-(4-methylsulfonylphenyl)imidazo[1,2-a]pyrimidine Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)N2C=CC=NC2=N1 SSARXDLPJGIOOC-UHFFFAOYSA-N 0.000 claims description 3
206010009944 Colon cancer Diseases 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
208000029742 colonic neoplasm Diseases 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
VHQYBEUFSFJFDF-UHFFFAOYSA-N 2-(3-chloro-4-methoxyphenyl)-3-(4-methylsulfonylphenyl)imidazo[1,2-a]pyrimidine Chemical compound C1=C(Cl)C(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)N2C=CC=NC2=N1 VHQYBEUFSFJFDF-UHFFFAOYSA-N 0.000 claims description 2
HEDBESBDRYVCHB-UHFFFAOYSA-N 2-(4-chlorophenyl)-3-(4-methylsulfonylphenyl)imidazo[1,2-a]pyrimidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(Cl)=CC=2)N=C2N1C=CC=N2 HEDBESBDRYVCHB-UHFFFAOYSA-N 0.000 claims description 2
WZFGZCSDTVNFST-UHFFFAOYSA-N 2-(4-fluorophenyl)-3-(4-methylsulfonylphenyl)imidazo[1,2-a]pyrimidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(F)=CC=2)N=C2N1C=CC=N2 WZFGZCSDTVNFST-UHFFFAOYSA-N 0.000 claims description 2
RBPODQILINHERL-UHFFFAOYSA-N 2-(4-methylphenyl)-3-(4-methylsulfonylphenyl)imidazo[1,2-a]pyrimidine Chemical compound C1=CC(C)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)N2C=CC=NC2=N1 RBPODQILINHERL-UHFFFAOYSA-N 0.000 claims description 2
MREPIUCTDXEEHJ-UHFFFAOYSA-N 7-methyl-2-(4-methylphenyl)-3-(4-methylsulfonylphenyl)imidazo[1,2-a]pyrimidine Chemical compound C1=CC(C)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)N2C=CC(C)=NC2=N1 MREPIUCTDXEEHJ-UHFFFAOYSA-N 0.000 claims description 2
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 4
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
208000016057 CHAND syndrome Diseases 0.000 claims 2
201000011510 cancer Diseases 0.000 claims 2
MMTGPHUVVVBSCZ-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-3-(4-methylsulfonylphenyl)imidazo[1,2-a]pyrimidine Chemical compound C1=C(OC)C(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)N2C=CC=NC2=N1 MMTGPHUVVVBSCZ-UHFFFAOYSA-N 0.000 claims 1
DQPPTYLEJWHRSJ-UHFFFAOYSA-N 2-(3,4-dimethylphenyl)-3-(4-methylsulfonylphenyl)imidazo[1,2-a]pyrimidine Chemical compound C1=C(C)C(C)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)N2C=CC=NC2=N1 DQPPTYLEJWHRSJ-UHFFFAOYSA-N 0.000 claims 1
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
229940125810 compound 20 Drugs 0.000 claims 1
238000006482 condensation reaction Methods 0.000 claims 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 1
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract description 21
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 abstract description 10
108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 abstract description 9
238000006243 chemical reaction Methods 0.000 abstract description 9
229910052757 nitrogen Inorganic materials 0.000 abstract description 7
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract description 6
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract description 6
125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract description 5
230000001562 ulcerogenic effect Effects 0.000 abstract description 2
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 78
239000000543 intermediate Substances 0.000 description 61
239000007787 solid Substances 0.000 description 42
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 36
239000000243 solution Substances 0.000 description 32
101150041968 CDC13 gene Proteins 0.000 description 24
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
239000000203 mixture Substances 0.000 description 24
239000000047 product Substances 0.000 description 24
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
108010037462 Cyclooxygenase 2 Proteins 0.000 description 20
239000012044 organic layer Substances 0.000 description 18
229910000030 sodium bicarbonate Inorganic materials 0.000 description 18
229960001407 sodium bicarbonate Drugs 0.000 description 18
235000017557 sodium bicarbonate Nutrition 0.000 description 18
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
239000011541 reaction mixture Substances 0.000 description 14
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
150000002576 ketones Chemical class 0.000 description 13
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
239000012267 brine Substances 0.000 description 8
229940093499 ethyl acetate Drugs 0.000 description 8
235000019439 ethyl acetate Nutrition 0.000 description 8
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 7
LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 7
MJIWQHRXSLOUJN-UHFFFAOYSA-N 1,2,4-triazin-3-amine Chemical compound NC1=NC=CN=N1 MJIWQHRXSLOUJN-UHFFFAOYSA-N 0.000 description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
ALLZHRSBDMRFHK-UHFFFAOYSA-N 4-(1-bromo-2-oxo-2-phenylethyl)benzenesulfonamide Chemical class C1=CC(S(=O)(=O)N)=CC=C1C(Br)C(=O)C1=CC=CC=C1 ALLZHRSBDMRFHK-UHFFFAOYSA-N 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000002274 desiccant Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
HSXSJJWWKGGAKE-UHFFFAOYSA-N 2-(4-methylsulfanylphenyl)acetyl chloride Chemical compound CSC1=CC=C(CC(Cl)=O)C=C1 HSXSJJWWKGGAKE-UHFFFAOYSA-N 0.000 description 4
QMECXXLIFMEZPK-UHFFFAOYSA-N 2-bromo-1-(3-chloro-4-methoxyphenyl)-2-(4-methylsulfonylphenyl)ethanone Chemical compound C1=C(Cl)C(OC)=CC=C1C(=O)C(Br)C1=CC=C(S(C)(=O)=O)C=C1 QMECXXLIFMEZPK-UHFFFAOYSA-N 0.000 description 4
KGITUXXEUNGDGD-UHFFFAOYSA-N 2-bromo-1-(3-fluoro-4-methoxyphenyl)-2-(4-methylsulfonylphenyl)ethanone Chemical compound C1=C(F)C(OC)=CC=C1C(=O)C(Br)C1=CC=C(S(C)(=O)=O)C=C1 KGITUXXEUNGDGD-UHFFFAOYSA-N 0.000 description 4
RBHURFRUCSUMPN-UHFFFAOYSA-N 2-bromo-2-(4-methylsulfonylphenyl)-1-phenylethanone Chemical class C1=CC(S(=O)(=O)C)=CC=C1C(Br)C(=O)C1=CC=CC=C1 RBHURFRUCSUMPN-UHFFFAOYSA-N 0.000 description 4
UNNFKIGEZGSMLJ-UHFFFAOYSA-N 4-[1-bromo-2-(4-methoxyphenyl)-2-oxoethyl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1C(=O)C(Br)C1=CC=C(S(N)(=O)=O)C=C1 UNNFKIGEZGSMLJ-UHFFFAOYSA-N 0.000 description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
229960000583 acetic acid Drugs 0.000 description 4
239000002253 acid Substances 0.000 description 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
229960004132 diethyl ether Drugs 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000012362 glacial acetic acid Substances 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
YCSLTCUBFAFEGB-UHFFFAOYSA-N 1-(3-fluorophenyl)-2-phenylethanone Chemical compound FC1=CC=CC(C(=O)CC=2C=CC=CC=2)=C1 YCSLTCUBFAFEGB-UHFFFAOYSA-N 0.000 description 3
ISPVOYAGIQMXEY-UHFFFAOYSA-N 4-[1-bromo-2-(3-fluorophenyl)-2-oxoethyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C(Br)C(=O)C1=CC=CC(F)=C1 ISPVOYAGIQMXEY-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
229940124599 anti-inflammatory drug Drugs 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
229940111134 coxibs Drugs 0.000 description 3
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000010410 layer Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 2
FHRZPTXMKRPRQF-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)ethanone Chemical compound C1=CC(S(=O)(=O)C)=CC=C1CC(=O)C1=CC=C(F)C=C1 FHRZPTXMKRPRQF-UHFFFAOYSA-N 0.000 description 2
NHPRLAQNUKVNHP-UHFFFAOYSA-N 2-(3-fluoro-4-methoxyphenyl)-3-(4-methylsulfonylphenyl)imidazo[1,2-a]pyrimidine Chemical compound C1=C(F)C(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)N2C=CC=NC2=N1 NHPRLAQNUKVNHP-UHFFFAOYSA-N 0.000 description 2
HPVDCBVHISKCIZ-UHFFFAOYSA-N 2-bromo-1-(4-fluorophenyl)-2-(4-methylsulfonylphenyl)ethanone Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(Br)C(=O)C1=CC=C(F)C=C1 HPVDCBVHISKCIZ-UHFFFAOYSA-N 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
IOYRSGXFRALSFE-UHFFFAOYSA-N 4-[1-bromo-2-(3-chloro-4-methoxyphenyl)-2-oxoethyl]benzenesulfonamide Chemical compound C1=C(Cl)C(OC)=CC=C1C(=O)C(Br)C1=CC=C(S(N)(=O)=O)C=C1 IOYRSGXFRALSFE-UHFFFAOYSA-N 0.000 description 2
PDGNMDCHPLNUEB-UHFFFAOYSA-N 4-[1-bromo-2-(4-fluorophenyl)-2-oxoethyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C(Br)C(=O)C1=CC=C(F)C=C1 PDGNMDCHPLNUEB-UHFFFAOYSA-N 0.000 description 2
GDRKUJAWMONTEK-UHFFFAOYSA-N 4-[2-(3-fluorophenyl)-2-oxoethyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CC(=O)C1=CC=CC(F)=C1 GDRKUJAWMONTEK-UHFFFAOYSA-N 0.000 description 2
LLRYEJYYLTWDCT-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)-2-oxoethyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CC(=O)C1=CC=C(F)C=C1 LLRYEJYYLTWDCT-UHFFFAOYSA-N 0.000 description 2
UJIAJDJCYWIULU-UHFFFAOYSA-N 4-[2-(4-methoxyphenyl)-2-oxoethyl]benzenesulfonamide Chemical compound C1=CC(OC)=CC=C1C(=O)CC1=CC=C(S(N)(=O)=O)C=C1 UJIAJDJCYWIULU-UHFFFAOYSA-N 0.000 description 2
DTWNAXOSHMXQAO-UHFFFAOYSA-N 4-[2-(4-methylphenyl)-2-oxoethyl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1C(=O)CC1=CC=C(S(N)(=O)=O)C=C1 DTWNAXOSHMXQAO-UHFFFAOYSA-N 0.000 description 2
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
ADDQDQRGILNXTJ-UHFFFAOYSA-N 4-phenacylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CC(=O)C1=CC=CC=C1 ADDQDQRGILNXTJ-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000002585 base Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 2
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
229960002986 dinoprostone Drugs 0.000 description 2
239000012458 free base Substances 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
150000005234 imidazo[1,2-a]pyridines Chemical class 0.000 description 2
238000011534 incubation Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
229940127293 prostanoid Drugs 0.000 description 2
150000003814 prostanoids Chemical class 0.000 description 2
LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
238000010992 reflux Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
OTKCEEWUXHVZQI-UHFFFAOYSA-N 1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(=O)CC1=CC=CC=C1 OTKCEEWUXHVZQI-UHFFFAOYSA-N 0.000 description 1
LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-Bis(diphenylphosphino)propane Substances C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 1
YQLFFKXSRHRZGZ-UHFFFAOYSA-N 1-(3-fluoro-4-methoxyphenyl)-2-phenylethanone Chemical compound C1=C(F)C(OC)=CC=C1C(=O)CC1=CC=CC=C1 YQLFFKXSRHRZGZ-UHFFFAOYSA-N 0.000 description 1
OWGQARUDUNKEDG-UHFFFAOYSA-N 1-(3-fluorophenyl)-2-phenylethanol Chemical compound C=1C=CC(F)=CC=1C(O)CC1=CC=CC=C1 OWGQARUDUNKEDG-UHFFFAOYSA-N 0.000 description 1
PZALLBFMHUWATO-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-(4-methylsulfanylphenyl)ethanone Chemical compound C1=CC(SC)=CC=C1CC(=O)C1=CC=C(F)C=C1 PZALLBFMHUWATO-UHFFFAOYSA-N 0.000 description 1
PLALKSRAHVYFOH-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-phenylethanone Chemical compound C1=CC(OC)=CC=C1C(=O)CC1=CC=CC=C1 PLALKSRAHVYFOH-UHFFFAOYSA-N 0.000 description 1
RDBAEHHVVNBKBB-UHFFFAOYSA-N 1-(4-methylphenyl)-2-phenylethanone Chemical compound C1=CC(C)=CC=C1C(=O)CC1=CC=CC=C1 RDBAEHHVVNBKBB-UHFFFAOYSA-N 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
OTDGVNZPSWUFLR-UHFFFAOYSA-N 2-(3-chloro-4-methoxyphenyl)-3-(4-methylsulfonylphenyl)imidazo[1,2-a]pyridine Chemical compound C1=C(Cl)C(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(C)(=O)=O)N2C=CC=CC2=N1 OTDGVNZPSWUFLR-UHFFFAOYSA-N 0.000 description 1
KWEALESHUQSTJZ-UHFFFAOYSA-N 2-(4-bromophenyl)-3-(4-methylsulfonylphenyl)imidazo[1,2-a]pyrimidine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC(Br)=CC=2)N=C2N1C=CC=N2 KWEALESHUQSTJZ-UHFFFAOYSA-N 0.000 description 1
BXNLTAIOFQRLJP-UHFFFAOYSA-N 2-(4-fluorophenyl)imidazo[1,2-a]pyrimidine Chemical compound C1=CC(F)=CC=C1C1=CN(C=CC=N2)C2=N1 BXNLTAIOFQRLJP-UHFFFAOYSA-N 0.000 description 1
GUEJEXCTWVCAGC-UHFFFAOYSA-N 2-bromo-1-(3-fluoro-4-methoxyphenyl)ethanone Chemical compound COC1=CC=C(C(=O)CBr)C=C1F GUEJEXCTWVCAGC-UHFFFAOYSA-N 0.000 description 1
WYDOBOIQVZNHJZ-UHFFFAOYSA-N 2-bromo-1-(4-methoxyphenyl)-2-(4-methylsulfonylphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1C(=O)C(Br)C1=CC=C(S(C)(=O)=O)C=C1 WYDOBOIQVZNHJZ-UHFFFAOYSA-N 0.000 description 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
MCWXURKAYCFNSW-UHFFFAOYSA-N 2-methylsulfanyl-2-phenylacetyl chloride Chemical compound CSC(C(Cl)=O)C1=CC=CC=C1 MCWXURKAYCFNSW-UHFFFAOYSA-N 0.000 description 1
PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
ZITBWPAMEWGAOY-UHFFFAOYSA-N 4-[1-bromo-2-(3-fluoro-4-methoxyphenyl)-2-oxoethyl]benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1C(=O)C(Br)C1=CC=C(S(N)(=O)=O)C=C1 ZITBWPAMEWGAOY-UHFFFAOYSA-N 0.000 description 1
RVALEUXWBMVKRL-UHFFFAOYSA-N 4-[1-bromo-2-(4-methylphenyl)-2-oxoethyl]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1C(=O)C(Br)C1=CC=C(S(N)(=O)=O)C=C1 RVALEUXWBMVKRL-UHFFFAOYSA-N 0.000 description 1
CKIRTZQDADDECF-UHFFFAOYSA-N 4-[2-(3-chloro-4-methoxyphenyl)-2-oxoethyl]benzenesulfonamide Chemical compound C1=C(Cl)C(OC)=CC=C1C(=O)CC1=CC=C(S(N)(=O)=O)C=C1 CKIRTZQDADDECF-UHFFFAOYSA-N 0.000 description 1
TVKPYCZZVUBVFS-UHFFFAOYSA-N 4-[2-(3-fluoro-4-methoxyphenyl)-2-oxoethyl]benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1C(=O)CC1=CC=C(S(N)(=O)=O)C=C1 TVKPYCZZVUBVFS-UHFFFAOYSA-N 0.000 description 1
VNHBYKHXBCYPBJ-UHFFFAOYSA-N 5-ethynylimidazo[1,2-a]pyridine Chemical compound C#CC1=CC=CC2=NC=CN12 VNHBYKHXBCYPBJ-UHFFFAOYSA-N 0.000 description 1
BWJHJLINOYAPEG-HOTGVXAUSA-N 8-chloro-6-[(6-chloropyridin-3-yl)methyl]-3-[(1S,2S)-2-hydroxycyclopentyl]-7-methyl-2H-1,3-benzoxazin-4-one Chemical compound ClC1=C(C(=CC=2C(N(COC=21)[C@@H]1[C@H](CCC1)O)=O)CC=1C=NC(=CC=1)Cl)C BWJHJLINOYAPEG-HOTGVXAUSA-N 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
208000027496 Behcet disease Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 1
201000011240 Frontotemporal dementia Diseases 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
206010017943 Gastrointestinal conditions Diseases 0.000 description 1
206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
206010028836 Neck pain Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
JWIPGAFCGUDKEY-UHFFFAOYSA-L O[Cr](Cl)(=O)=O.C1=CC=NC=C1 Chemical compound O[Cr](Cl)(=O)=O.C1=CC=NC=C1 JWIPGAFCGUDKEY-UHFFFAOYSA-L 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000000609 Pick Disease of the Brain Diseases 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
206010038910 Retinitis Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
208000010040 Sprains and Strains Diseases 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000009692 acute damage Effects 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
150000001266 acyl halides Chemical class 0.000 description 1
230000007815 allergy Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000002221 antipyretic Substances 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
229940073608 benzyl chloride Drugs 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical class BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000011903 deuterated solvents‎ Substances 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000003480 eluent Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
239000005457 ice water Substances 0.000 description 1
150000005238 imidazo[1,2-a]pyrimidines Chemical class 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000010907 mechanical stirring Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
IHYNKGRWCDKNEG-UHFFFAOYSA-N n-(4-bromophenyl)-2,6-dihydroxybenzamide Chemical compound OC1=CC=CC(O)=C1C(=O)NC1=CC=C(Br)C=C1 IHYNKGRWCDKNEG-UHFFFAOYSA-N 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
230000010309 neoplastic transformation Effects 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
229910000069 nitrogen hydride Inorganic materials 0.000 description 1
125000002734 organomagnesium group Chemical group 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
150000003815 prostacyclins Chemical class 0.000 description 1
YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000004044 response Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
230000016160 smooth muscle contraction Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229960001922 sodium perborate Drugs 0.000 description 1
229960003010 sodium sulfate Drugs 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
201000004595 synovitis Diseases 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 1
150000003595 thromboxanes Chemical class 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
208000004371 toothache Diseases 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
150000003918 triazines Chemical class 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

OA1200100033A 1998-08-03 1999-07-23 Substituted imidazo!1,2aÜazines as selective inhibitors of cox-2. OA11592A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES009801652A ES2140354B1 (es)	1998-08-03	1998-08-03	Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.

Publications (1)

Publication Number	Publication Date
OA11592A true OA11592A (en)	2004-07-30

Family

ID=8304755

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100033A OA11592A (en)	1998-08-03	1999-07-23	Substituted imidazo!1,2aÜazines as selective inhibitors of cox-2.

Country Status (30)

Country	Link
US (1)	US6670365B1 (fr)
EP (1)	EP1104762B1 (fr)
JP (1)	JP2002522438A (fr)
KR (1)	KR20010079602A (fr)
CN (1)	CN1131865C (fr)
AP (1)	AP2001002082A0 (fr)
AT (1)	ATE224391T1 (fr)
AU (1)	AU749770B2 (fr)
BG (1)	BG105299A (fr)
BR (1)	BR9912968A (fr)
CA (1)	CA2339187A1 (fr)
CZ (1)	CZ291783B6 (fr)
DE (1)	DE69903046T2 (fr)
DK (1)	DK1104762T3 (fr)
EA (1)	EA003399B1 (fr)
ES (2)	ES2140354B1 (fr)
HU (1)	HUP0103004A3 (fr)
ID (1)	ID28539A (fr)
IL (1)	IL141242A0 (fr)
MX (1)	MXPA01001332A (fr)
NO (1)	NO20010568L (fr)
NZ (1)	NZ510196A (fr)
OA (1)	OA11592A (fr)
PL (1)	PL345804A1 (fr)
PT (1)	PT1104762E (fr)
SK (1)	SK1662001A3 (fr)
TR (1)	TR200100359T2 (fr)
WO (1)	WO2000008024A1 (fr)
YU (1)	YU7401A (fr)
ZA (1)	ZA200101632B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA008242B1 (ru)	1999-12-08	2007-04-27	Фармация Корпорейшн	Композиции на основе ингибитора циклооксигеназы-2 с быстро наступающим терапевтическим действием и способы лечения заболеваний
US8241622B2 (en) *	2001-07-13	2012-08-14	University Of Iowa Research Foundation	Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
US20030100594A1 (en) *	2001-08-10	2003-05-29	Pharmacia Corporation	Carbonic anhydrase inhibitor
DE10247271A1 (de) *	2002-10-10	2004-08-26	Grünenthal GmbH	Substituierte C-Imidazo[1,2-a]pyridin-3-yle
DE10256881A1 (de) *	2002-12-05	2004-06-24	Beiersdorf Ag	Neue topische Verwendung von Bis-Arylimidazo[1,2-a]thiolanderivaten
ES2275218T3 (es)	2003-05-07	2007-06-01	Osteologix A/S	Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
WO2005014598A1 (fr) *	2003-07-30	2005-02-17	Laboratorios S.A.L.V.A.T., S.A.	Imidazopyrimidines substituees pour la prevention et le traitement du cancer
WO2007034278A2 (fr) *	2005-09-19	2007-03-29	Pfizer Products Inc.	Antagonistes du recepteur du c3a
WO2007079141A2 (fr) *	2005-12-30	2007-07-12	University Of Iowa Research Foundation	Procede d'identification de composes utiles pour le traitement de maladies degeneratives neuronales
WO2007096764A2 (fr) *	2006-02-27	2007-08-30	Glenmark Pharmaceuticals S.A.	Dérivés d'hétéroaryles bicycliques en tant que modulateurs des récepteurs cannabinoïdes
EP2220083B1 (fr) *	2007-11-14	2017-07-19	Janssen Pharmaceuticals, Inc.	Dérivés d'imidazo[1,2-a]pyridines et leur utilisation en tant que modulateurs allostériques positifs de récepteurs mglur2
CA2739303A1 (fr) *	2008-10-01	2010-04-08	Synta Pharmaceuticals Corp.	Composes pour des utilisations liees a une inflammation et au systeme immunitaire
GB201321732D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
WO2017139381A1 (fr)	2016-02-08	2017-08-17	University Of Iowa Research Foundation	Procédés pour produire des virus adéno-associés/bocavirus parvovirus chimériques
US11684679B2 (en)	2016-03-07	2023-06-27	University Of Iowa Research Foundation	AAV-mediated expression using a synthetic promoter and enhancer
WO2017205739A1 (fr)	2016-05-26	2017-11-30	University Of Iowa Research Foundation	Configurations cis et trans pour la résolution terminale du bocavirus 1 humain
WO2018132747A1 (fr)	2017-01-13	2018-07-19	University Of Iowa Research Foundation	Petit arn non codant pour bocaparvovirus et ses utilisations
CA3209491A1 (fr)	2021-03-15	2022-09-22	Saul Yedgar	Dipalmitoyl-phosphatidyl-ethanol-amine conjuguee a l'acide hyaluronique en combinaison avec des medicaments anti-inflammatoires non steroidiens (ains) pour traiter ou soulager des maladies inflammatoire

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2785133A (en) *	1954-03-26	1957-03-12	Gen Aniline & Film Corp	Compositions for a method of whitening fine fabrics
US3455924A (en) *	1967-02-08	1969-07-15	Upjohn Co	Dianisylimidazoles
WO1992010190A1 (fr)	1990-12-13	1992-06-25	Smithkline Beecham Corporation	Nouveaux medicaments anti-inflammatoires suppresseurs de cytokine
AU3648993A (en) *	1992-03-17	1993-10-21	Nippon Shinyaku Co. Ltd.	Imidazopyridine derivative and medicine
US5620999A (en) *	1994-07-28	1997-04-15	Weier; Richard M.	Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
KR19980703559A (ko) *	1995-04-04	1998-11-05	그레이엄브레레톤	이미다조［1,2-ａ］피리딘 유도체
UA57002C2 (uk) *	1995-10-13	2003-06-16	Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі.	Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування

1998
- 1998-08-03 ES ES009801652A patent/ES2140354B1/es not_active Expired - Lifetime
1999
- 1999-07-23 AU AU47824/99A patent/AU749770B2/en not_active Ceased
- 1999-07-23 IL IL14124299A patent/IL141242A0/xx unknown
- 1999-07-23 SK SK166-2001A patent/SK1662001A3/sk unknown
- 1999-07-23 JP JP2000563657A patent/JP2002522438A/ja active Pending
- 1999-07-23 PT PT99931266T patent/PT1104762E/pt unknown
- 1999-07-23 CA CA002339187A patent/CA2339187A1/fr not_active Abandoned
- 1999-07-23 YU YU7401A patent/YU7401A/sh unknown
- 1999-07-23 TR TR2001/00359T patent/TR200100359T2/xx unknown
- 1999-07-23 WO PCT/ES1999/000235 patent/WO2000008024A1/fr not_active Ceased
- 1999-07-23 OA OA1200100033A patent/OA11592A/en unknown
- 1999-07-23 ES ES99931266T patent/ES2182546T3/es not_active Expired - Lifetime
- 1999-07-23 MX MXPA01001332A patent/MXPA01001332A/es unknown
- 1999-07-23 PL PL99345804A patent/PL345804A1/xx not_active IP Right Cessation
- 1999-07-23 US US09/762,146 patent/US6670365B1/en not_active Expired - Fee Related
- 1999-07-23 AT AT99931266T patent/ATE224391T1/de not_active IP Right Cessation
- 1999-07-23 CN CN998116750A patent/CN1131865C/zh not_active Expired - Fee Related
- 1999-07-23 CZ CZ2001433A patent/CZ291783B6/cs not_active IP Right Cessation
- 1999-07-23 EA EA200100212A patent/EA003399B1/ru not_active IP Right Cessation
- 1999-07-23 KR KR1020017001453A patent/KR20010079602A/ko not_active Ceased
- 1999-07-23 DE DE69903046T patent/DE69903046T2/de not_active Expired - Fee Related
- 1999-07-23 AP APAP/P/2001/002082A patent/AP2001002082A0/en unknown
- 1999-07-23 DK DK99931266T patent/DK1104762T3/da active
- 1999-07-23 HU HU0103004A patent/HUP0103004A3/hu unknown
- 1999-07-23 BR BR9912968-0A patent/BR9912968A/pt not_active IP Right Cessation
- 1999-07-23 EP EP99931266A patent/EP1104762B1/fr not_active Expired - Lifetime
- 1999-07-23 NZ NZ510196A patent/NZ510196A/xx unknown
- 1999-07-23 ID IDW20010517A patent/ID28539A/id unknown
2001
- 2001-02-02 NO NO20010568A patent/NO20010568L/no not_active Application Discontinuation
- 2001-02-27 ZA ZA200101632A patent/ZA200101632B/en unknown
- 2001-02-28 BG BG105299A patent/BG105299A/xx unknown

Also Published As

Publication number	Publication date
EA200100212A1 (ru)	2001-08-27
NO20010568D0 (no)	2001-02-02
DE69903046T2 (de)	2003-05-22
AU4782499A (en)	2000-02-28
WO2000008024A1 (fr)	2000-02-17
ZA200101632B (en)	2001-08-30
PT1104762E (pt)	2002-11-29
PL345804A1 (en)	2002-01-02
NZ510196A (en)	2002-09-27
DK1104762T3 (da)	2002-10-21
YU7401A (sh)	2003-10-31
BR9912968A (pt)	2001-05-08
MXPA01001332A (es)	2002-11-29
DE69903046D1 (de)	2002-10-24
BG105299A (en)	2001-11-30
AP2001002082A0 (en)	2001-03-31
CN1321157A (zh)	2001-11-07
SK1662001A3 (en)	2001-08-06
US6670365B1 (en)	2003-12-30
CN1131865C (zh)	2003-12-24
NO20010568L (no)	2001-04-02
EP1104762B1 (fr)	2002-09-18
HUP0103004A2 (hu)	2002-01-28
AU749770B2 (en)	2002-07-04
CZ291783B6 (cs)	2003-05-14
EA003399B1 (ru)	2003-04-24
HK1037629A1 (en)	2002-02-15
ES2140354A1 (es)	2000-02-16
HUP0103004A3 (en)	2003-03-28
EP1104762A1 (fr)	2001-06-06
ES2182546T3 (es)	2003-03-01
CZ2001433A3 (cs)	2001-08-15
IL141242A0 (en)	2002-03-10
TR200100359T2 (tr)	2001-06-21
ES2140354B1 (es)	2000-11-01
JP2002522438A (ja)	2002-07-23
ATE224391T1 (de)	2002-10-15
ID28539A (id)	2001-05-31
KR20010079602A (ko)	2001-08-22
CA2339187A1 (fr)	2000-02-17

Publication	Publication Date	Title
AU749770B2 (en)	2002-07-04	Substituted imidazo(1,2A)azines as selective inhibitors of COX-2
US5891895A (en)	1999-04-06	Hydroxypyridine derivatives their production and use
CA2200210A1 (fr)	1996-04-04	Pyrrolo[2,3-d]pyrimidines et leur utilisation
KR20020015350A (ko)	2002-02-27	사이클록시게나아제-2의 억제제로서 1-(4-설파밀아릴)-3-치환형-5-아릴-2-피라졸린
CN1232463A (zh)	1999-10-20	吡唑并吡啶基哒嗪酮衍生物及其制备方法
US5723485A (en)	1998-03-03	1,2-Diarylindole derivatives, processes for their preparation and their uses in therapeutics
EP1660500A1 (fr)	2006-05-31	Imidazopyrimidines substituees pour la prevention et le traitement du cancer
JPH09503792A (ja)	1997-04-15	新規なチアゾリジン−４−オン誘導体
KR100715918B1 (ko)	2007-05-08	항-염증 활성을 갖는 신규 이미다졸
CZ20011058A3 (cs)	2001-08-15	Deriváty 2-fenylpyran-4-onu
HUT62888A (en)	1993-06-28	Process for producing new oxazole derivatives and pharmaceutical compositions comprising same
US20050245750A1 (en)	2005-11-03	Process for preparing 1,3-benzodioxole-2-spirocycloalkane derivative
KR102674919B1 (ko)	2024-06-12	3-브로모-5-(2-에틸이미다조[1,2-a]피리딘-3-카르보닐)-2-하이드록시벤조니트릴의 합성
JP4131337B2 (ja)	2008-08-13	３―（イソオキサゾール―５―イル）置換安息香酸誘導体およびその製造法
JPH04297461A (ja)	1992-10-21	２−チオヒダントイン誘導体
HK1037629B (en)	2003-05-02	Substituted imidazo [1,2a]azines as selective inhibitors of cox-2
KR20020087942A (ko)	2002-11-23	항염증 활성이 있는 신규 이미다졸 유도체
JPWO1997035850A1 (ja)	1999-05-18	３−（イソオキサゾール−５−イル）置換安息香酸誘導体およびその製造法
JP2711435B2 (ja)	1998-02-10	新規な２，３−ジヒドロ−４ｈ−１−ベンゾピラン−４−オン誘導体またはその塩
SK4202000A3 (en)	2000-10-09	Process of making 3-aryloxy-4-aryl furan-2-ones useful as inhibitors of cox-2
JPH0576462B2 (fr)	1993-10-22
NO326162B1 (no)	2008-10-13	Fremgangsmate for fremstilling av 4-(imidazol-1-yl)benzensulfonamidderivater.
CN120865165A (zh)	2025-10-31	一种具有手性中心的二芳基季碳吡唑酮化合物的合成方法
KR0139260B1 (ko)	1998-05-15	고리화된 이미다졸을 가지는 벤즈이미다졸 유도체
JPS5818362A (ja)	1983-02-02	イソキノリン誘導体およびその製造法